(MAZE) Maze Therapeutics, Common - Overview
Stock: MZE829, MZE782, MZE001, Renal, Cardiovascular
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 73.6% |
| Relative Tail Risk | -5.83% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.70 |
| Alpha | 252.11 |
| Character TTM | |
|---|---|
| Beta | 0.922 |
| Beta Downside | 0.601 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.69% |
| CAGR/Max DD | 3.64 |
Description: MAZE Maze Therapeutics, Common December 26, 2025
Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biopharma focused on orally administered small-molecule precision medicines targeting renal, cardiovascular, metabolic disorders and obesity in the U.S. Its lead pipeline comprises MZE829, a Phase II APOL1 inhibitor for APOL1-associated kidney disease, and MZE782, a Phase I SLC6A19 inhibitor for chronic kidney disease, plus MZE001 for Pompe disease. The company was incorporated in 2017 (formerly Modulus Therapeutics) and is headquartered in South San Francisco.
Key external drivers: (1) The global chronic kidney disease market is projected to exceed $100 billion by 2028, providing a sizable addressable pool for MZE829 and MZE782. (2) APOL1 risk variants affect roughly 13 % of individuals of African ancestry, translating to an estimated 1–2 million U.S. patients with heightened CKD risk-a niche but high-unmet-need segment. (3) Biotech R&D efficiency remains low; historically only ~10 % of Phase II programs progress to approval, underscoring the importance of clear mechanistic data and biomarker-driven trial designs for Maze’s success.
For a data-driven deep-dive into MAZE’s valuation assumptions and comparable peer metrics, you may find ValueRay’s analytical toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -126.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA -65.70 > 1.0 |
| NWC/Revenue: 220.4% < 20% (prev 81.43%; Δ 139.0% < -1%) |
| CFO/TA -0.25 > 3% & CFO -106.7m > Net Income -126.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.8m) vs 12m ago 4.57% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 54.51% > 50% (prev 87.02%; Δ -32.51% > 0%) |
| Interest Coverage Ratio: -51.83 > 6 (EBITDA TTM -126.3m / Interest Expense TTM -2.49m) |
Altman Z'' -11.80
| A: 0.87 (Total Current Assets 391.3m - Total Current Liabilities 22.1m) / Total Assets 422.1m |
| B: -1.08 (Retained Earnings -455.0m / Total Assets 422.1m) |
| C: -0.42 (EBIT TTM -128.9m / Avg Total Assets 307.3m) |
| D: -10.67 (Book Value of Equity -454.9m / Total Liabilities 42.6m) |
| Altman-Z'' Score: -11.80 = D |
What is the price of MAZE shares?
Over the past week, the price has changed by +2.54%, over one month by +18.33%, over three months by +56.48% and over the past year by +268.13%.
Is MAZE a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MAZE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.4 | 3.6% |
| Analysts Target Price | 49.4 | 3.6% |
| ValueRay Target Price | 55.6 | 16.5% |
MAZE Fundamental Data Overview February 07, 2026
P/B = 6.1126
Revenue TTM = 167.5m USD
EBIT TTM = -128.9m USD
EBITDA TTM = -126.3m USD
Long Term Debt = 24.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.76m USD (from shortTermDebt, last quarter)
Debt = 24.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -292.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.76b USD (2.11b + Debt 24.2m - CCE 383.9m)
Interest Coverage Ratio = -51.83 (Ebit TTM -128.9m / Interest Expense TTM -2.49m)
EV/FCF = -16.25x (Enterprise Value 1.76b / FCF TTM -108.0m)
FCF Yield = -6.16% (FCF TTM -108.0m / Enterprise Value 1.76b)
FCF Margin = -64.49% (FCF TTM -108.0m / Revenue TTM 167.5m)
Net Margin = -75.30% (Net Income TTM -126.1m / Revenue TTM 167.5m)
Gross Margin = unknown ((Revenue TTM 167.5m - Cost of Revenue TTM 2.04m) / Revenue TTM)
Tobins Q-Ratio = 4.16 (Enterprise Value 1.76b / Total Assets 422.1m)
Interest Expense / Debt = -10.28% (Interest Expense -2.49m / Debt 24.2m)
Taxrate = 2.19% (1.17m / 53.4m)
NOPAT = -126.1m (EBIT -128.9m * (1 - 2.19%)) [loss with tax shield]
Current Ratio = 17.70 (Total Current Assets 391.3m / Total Current Liabilities 22.1m)
Debt / Equity = 0.06 (Debt 24.2m / totalStockholderEquity, last quarter 379.4m)
Debt / EBITDA = 2.32 (negative EBITDA) (Net Debt -292.6m / EBITDA -126.3m)
Debt / FCF = 2.71 (negative FCF - burning cash) (Net Debt -292.6m / FCF TTM -108.0m)
Total Stockholder Equity = 282.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.05% (Net Income -126.1m / Total Assets 422.1m)
RoE = -44.62% (Net Income TTM -126.1m / Total Stockholder Equity 282.7m)
RoCE = -42.01% (EBIT -128.9m / Capital Employed (Equity 282.7m + L.T.Debt 24.2m))
RoIC = -81.00% (negative operating profit) (NOPAT -126.1m / Invested Capital 155.6m)
WACC = 9.20% (E(2.11b)/V(2.14b) * Re(9.31%) + (debt cost/tax rate unavailable))
Discount Rate = 9.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.26%
Fair Price DCF = unknown (Cash Flow -108.0m)
EPS Correlation: 83.60 | EPS CAGR: 0.0% | SUE: N/A | # QB: 0
Revenue Correlation: -13.63 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.76 | Chg30d=+0.030 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=-3.15 | Chg30d=+0.050 | Revisions Net=+1 | Growth EPS=-2.5% | Growth Revenue=+0.0%